RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.6B
This Quarter Return
+8.38%
1 Year Return
+25.98%
3 Year Return
+194.74%
5 Year Return
+336.76%
10 Year Return
+2,199.29%
AUM
$1.6B
AUM Growth
+$1.6B
(-8.2%)
Cap. Flow
-$238M
Cap. Flow
% of AUM
-14.81%
Top 10 Holdings %
Top 10 Hldgs %
36.09%
Holding
105
New
9
Increased
32
Reduced
29
Closed
12
Top Buys
| 1 |
Agios Pharmaceuticals
AGIO
|
$21.5M |
| 2 |
CAI
Caris Life Sciences, Inc. Common Stock
CAI
|
$21.2M |
| 3 |
OMDA
Omada Health, Inc. Common Stock
OMDA
|
$16.8M |
| 4 |
SPDR S&P Biotech ETF
XBI
|
$12.6M |
| 5 |
Arcellx
ACLX
|
$12.3M |
Top Sells
| 1 |
BPMC
Blueprint Medicines
BPMC
|
$105M |
| 2 |
Nuvalent
NUVL
|
$25.5M |
| 3 |
Neurocrine Biosciences
NBIX
|
$23.9M |
| 4 |
Legend Biotech
LEGN
|
$17.4M |
| 5 |
UnitedHealth
UNH
|
$15.6M |
Sector Composition
| 1 | Healthcare | 98.9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
51
Neurocrine Biosciences
NBIX
$13.8B
| $11.2M | 0.7% |
88,800
-190,200
| -68% | -$23.9M |
|
52
Pharvaris
PHVS
$1.39B
| $11M | 0.68% |
623,402
| – | – |
|
53
Edwards Lifesciences
EW
$47.8B
| $10.2M | 0.64% |
131,000
-124,000
| -49% | -$9.7M |
|
54
NewAmsterdam Pharma
NAMS
$2.71B
| $9.71M | 0.61% |
536,111
| – | – |
|
55
Ardelyx
ARDX
$1.53B
| $8.96M | 0.56% |
2,286,273
+681,298
| +42% | +$2.67M |
|
|
56
Nuvalent
NUVL
$5.52B
| $7.12M | 0.44% |
93,328
-334,204
| -78% | -$25.5M |
|
57
Aclaris Therapeutics
ACRS
$209M
| $6.77M | 0.42% |
4,769,309
-277,000
| -5% | -$393K |
|
58
Cidara Therapeutics
CDTX
$1.66B
| $6.53M | 0.41% |
+134,133
| New | +$6.53M |
|
|
ZBIO
59
Zenas BioPharma, Inc. Common Stock
ZBIO
$674M
| $6.21M | 0.39% |
640,467
-238,200
| -27% | -$2.31M |
|
60
Regeneron Pharmaceuticals
REGN
$61.5B
| $5.93M | 0.37% |
11,300
+8,500
| +304% | +$4.46M |
|
61
Cogent Biosciences
COGT
$1.69B
| $5.75M | 0.36% |
+800,199
| New | +$5.75M |
|
62
Dyne Therapeutics
DYN
$1.92B
| $5.53M | 0.34% |
580,998
+56,499
| +11% | +$538K |
|
63
Cullinan Oncology
CGEM
$445M
| $5.03M | 0.31% |
668,233
+23,600
| +4% | +$178K |
|
64
Janux Therapeutics
JANX
$1.37B
| $4.86M | 0.3% |
210,266
+5,800
| +3% | +$134K |
|
65
Mineralys Therapeutics
MLYS
$1.03B
| $4.39M | 0.27% |
324,513
+3,700
| +1% | +$50.1K |
|
66
Thermo Fisher Scientific
TMO
$186B
| $4.05M | 0.25% |
+10,000
| New | +$4.05M |
|
67
Gossamer Bio
GOSS
$562M
| $4.02M | 0.25% |
3,266,960
| – | – |
|
68
Immunovant
IMVT
$2.56B
| $3.54M | 0.22% |
221,500
-754,303
| -77% | -$12.1M |
|
69
Amylyx Pharmaceuticals
AMLX
$836M
| $3.2M | 0.2% |
499,764
+156,536
| +46% | +$1M |
|
|
BCAX
70
Bicara Therapeutics Inc. Common Stock
BCAX
$651M
| $3.12M | 0.19% |
336,070
| – | – |
|
71
Jasper Therapeutics
JSPR
$45.5M
| $3.03M | 0.19% |
545,171
| – | – |
|
72
Prothena Corp
PRTA
$441M
| $2.99M | 0.19% |
492,601
| – | – |
|
73
Alphatec Holdings
ATEC
$2.35B
| $2.97M | 0.19% |
267,500
| – | – |
|
|
LENZ
74
LENZ Therapeutics
LENZ
$1.1B
| $2.46M | 0.15% |
83,982
+900
| +1% | +$26.4K |
|
|
EDAP
75
EDAP TMS
EDAP
$84.5M
| $2.1M | 0.13% |
1,270,000
| – | – |
|